^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Urothelial Cancer

    Related cancers:
    1d
    Indoxyl sulfate promoted glutamine metabolism and cell proliferation in urothelial carcinoma involving Runx2. (PubMed, Biomed Pharmacother)
    The cancer-promoting effects of indoxyl sulfate were further demonstrated in tumor-bearing mice. In short, our results suggest that indoxyl sulfate may act as a bridge in linking the gap between CKD and urothelial carcinoma by involving the enhancement of glutamine uptake and metabolism.
    Journal
    |
    SLC1A5 (Solute Carrier Family 1 Member 5) • MIR204 (MicroRNA 204) • RUNX2 (RUNX Family Transcription Factor 2)
    1d
    Virus-induced APOBEC3 transmutagenesis in bladder cancer initiation. (PubMed, Sci Adv)
    "Transmutagenesis" explains how cells proximal to infected neighbors acquire cancer-initiating mutations. This hypothesis for how urothelial cancers can develop as APOBEC3 signature rich, while remaining virus-negative, suggests that a large proportion of urothelial carcinomas may be preventable by antiviral intervention.
    Review • Journal
    |
    APOB (Apolipoprotein B)
    2d
    OASIS: Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers (clinicaltrials.gov)
    P2, N=400, Recruiting, UNICANCER
    New P2 trial
    |
    Enhertu (fam-trastuzumab deruxtecan-nxki)
    3d
    L1CAM/CD171 expression in human tumors and its association with tumor phenotype. (PubMed, Acta Oncol)
    The results highlighted a small number of tumor entities that could be targeted by anti-L1CAM drugs, once these are proved to be sufficiently safe and efficient. L1CAM expression does not appear to confer an aggressive phenotype to affected cancer cells.
    Journal
    |
    L1CAM (L1 cell adhesion molecule)
    3d
    Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial (clinicaltrials.gov)
    P2, N=111, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2026 --> Nov 2025
    Trial initiation date
    |
    Keytruda (pembrolizumab)
    3d
    Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations (clinicaltrials.gov)
    P2, N=17, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Nov 2025 --> Nov 2026
    Trial completion date
    |
    TSC2 (TSC complex subunit 2) • TSC1 (TSC complex subunit 1)
    |
    sapanisertib (CB-228)
    3d
    ARIANES: Efficacy and Safety of the Combination of Rucaparib (PARP Inhibitor) and Atezolizumab (Anti-PD-L1 Antibody) in Patients With DNA Repair-deficient or Platinum-sensitive Solid Tumors (clinicaltrials.gov)
    P2, N=130, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | Suspended --> Terminated; Bankruptcy of partner: Clovis
    Trial termination • Pan tumor • Platinum sensitive
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • CDK12 (Cyclin dependent kinase 12) • CHEK2 (Checkpoint kinase 2) • RAD51 (RAD51 Homolog A) • FANCA (FA Complementation Group A) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1) • RAD51C (RAD51 paralog C) • IL2 (Interleukin 2) • RAD51D (RAD51 paralog D) • BARD1 (BRCA1 Associated RING Domain 1) • NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)) • RAD54L (DNA Repair And Recombination Protein RAD54) • DRD (DNA Repair Deficiency)
    |
    DDR • CDK12 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • RAD51D mutation • BARD1 mutation
    |
    Tecentriq (atezolizumab) • Rubraca (rucaparib)
    6d
    Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, NeoTX Therapeutics Ltd. | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • TPBG (Trophoblast Glycoprotein)
    |
    HER-2 negative
    |
    Imfinzi (durvalumab) • Gazyva (obinutuzumab) • Anyara (naptumomab estafenatox)
    7d
    Integrative multi-omics and single-cell transcriptomics reveal ARHGEF12 driving chemoresistance in bladder cancer. (PubMed, Hereditas)
    This study is the first to integrate MR with single-cell transcriptomics to explore the genetic contribution to cisplatin resistance in BLCA. Our results uncover a novel mechanistic role of ARHGEF12 in BLCA progression and chemoresistance and suggest it as a potential therapeutic target for precision treatment strategies.
    Journal
    |
    RHOA (Ras homolog family member A)
    |
    cisplatin
    7d
    Towards biomarker-driven therapies for urothelial carcinoma. (PubMed, Nat Rev Clin Oncol)
    In the past few years, circulating tumour DNA has emerged as a minimally invasive biomarker, with increasing data supporting its prognostic value and utility for monitoring clinical responses. In this Review, we address these developments and discuss biomarkers that could have clinical utility in patients with aUC.
    Review • Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • TMB (Tumor Mutational Burden) • FGFR3 (Fibroblast growth factor receptor 3)
    |
    PD-L1 expression • HER-2 overexpression • HER-2 mutation • FGFR3 mutation
    7d
    scPER: A Rigorous Computational Approach to Determine Cellular Subtypes in Tumors Aligned With Cancer Phenotypes From Total RNA Sequencing. (PubMed, Adv Sci (Weinh))
    In metastatic urothelial cancer, scPER predicted TGFβ-mediated inhibition of CD4 naïve T cells to diminish PD-L1 checkpoint blockade efficacy. scPER enables robust integration of scRNA-seq datasets to estimate cellular proportions across tumors and identify clinically relevant cell populations.
    Journal
    |
    CD4 (CD4 Molecule) • TGFB1 (Transforming Growth Factor Beta 1) • SLAMF7 (SLAM Family Member 7)
    8d
    Clinical Experience with URO17® in the Diagnosis and Surveillance of Bladder Cancer. (PubMed, J Clin Med)
    In the seven illustrative cases presented, URO17® aided clinical decision-making as part of routine diagnostic and surveillance workflows. The test's integration with existing cytology processes supports its potential role as a noninvasive adjunct for evaluating patients with suspected or recurrent urothelial carcinoma.
    Journal
    |
    KRT17 (Keratin 17)
    |
    URO17™